Financial Performance - Revenue for the six months ended December 31, 2025, was RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million in the same period of 2024[14]. - Gross profit decreased by 32.7% to RMB 47.4 million from RMB 70.4 million year-on-year[14]. - The operating loss improved to RMB 3.4 million from RMB 7.9 million, a reduction of RMB 4.5 million[14]. - Adjusted EBITDA increased to RMB 3.3 million, up RMB 4.4 million from a loss of RMB 1.1 million in the previous year[14]. - Basic loss per share improved to RMB (6.21) cents from RMB (10.00) cents, a decrease of RMB 3.79 cents[14]. - Loss attributable to owners of the Company for the Period was RMB 6.1 million, an improvement from a loss of RMB 8.0 million in the same period of 2024[60]. - The Group recorded overall revenue of RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million for the corresponding period in 2024[60]. - Gross profit for the same period was RMB 47,448,000, down 32.5% from RMB 70,363,000 in 2024[158]. - Operating loss narrowed to RMB 3,406,000 from RMB 7,933,000 year-over-year[158]. - The company reported a comprehensive loss of RMB 6,058,000 for the period, which includes a loss of RMB 8,012,000 for the period and total other comprehensive income of RMB 2,249,000[162]. Liquidity and Financial Position - The current ratio increased to 1.5 from 1.3, indicating improved liquidity[14]. - Cash and cash equivalents significantly increased to RMB 63,096,000 from RMB 13,403,000, indicating improved liquidity[155]. - Net cash flows from operating activities amounted to RMB 21.1 million during the period, compared to RMB 8.7 million for the six months ended December 31, 2024[84]. - The Group had total borrowings from banks of RMB 25.0 million at an interest rate of 3.5% per annum, with a gearing ratio of N/A as of December 31, 2025, compared to 3.7% as of June 30, 2025[92]. - The total financial liabilities as of December 31, 2025, are RMB 25,856,000, slightly down from RMB 26,464,000 as of June 30, 2025[188]. - The financial liabilities due within less than 1 year amount to RMB 5,796,000, a significant increase from RMB 887,000 as of June 30, 2025[188]. Operational Efficiency - Trade receivables turnover days decreased to 29.2 days from 33.4 days, reflecting better collection efficiency[14]. - Inventory turnover days improved to 54.3 days from 57.5 days, indicating more efficient inventory management[14]. - Trade payables turnover days decreased significantly to 50.2 days from 80.6 days, suggesting improved payment terms[14]. - Selling and marketing expenses were RMB 32.8 million, a decrease of 45.3% from RMB 60.0 million in the previous year, accounting for 12.3% of the Group's revenue[74]. - Administrative expenses were RMB 18.1 million, a slight decrease of 2.7% from RMB 18.6 million in the previous year, accounting for 6.8% of the Group's revenue[76]. Market Trends and Strategic Focus - The healthcare industry in China is experiencing structural growth driven by population aging and high prevalence of chronic diseases, with a rising demand for chronic disease management and health foods[21][28]. - The Group is focusing on expanding its traditional retail chain stores and distribution network while implementing "Direct to Patient (DTP) pharmacies" to adapt to industry trends[30][33]. - The introduction of new service models, such as telephone ordering and home delivery, has enhanced overall service coverage and user experience[32][33]. - The Group is actively promoting digital transformation to improve its online operational infrastructure and build a more efficient network service system[34]. - The "new silver-haired generation" (aged 50-70) is increasingly emphasizing preventive health management, influencing market trends towards nutritional supplements and health monitoring devices[27][29]. - The Group is committed to enhancing employee training to optimize service capabilities within its retail chain system[31]. - The healthcare market potential is expected to expand further, driven by policy guidance, technological advancement, and rising health consumption awareness[28]. Corporate Governance and Compliance - The Company aims to expand its presence outside Mainland China to maximize shareholder returns and will evaluate viable options for this expansion[103]. - The Group will enhance its corporate governance practices to ensure compliance with the Corporate Governance Code[112]. - The company has complied with the Corporate Governance Code, with some deviations noted regarding the roles of chairman and CEO[110]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim results for the period[120]. Share Capital and Options - The Company issued 30,440,263 shares, representing approximately 27.54% of the enlarged issued share capital, at a subscription price of HK$0.08 per share[116]. - The subscription agreement was approved by shareholders in an extraordinary general meeting held on July 23, 2025[117]. - The company granted a total of 20,000,000 share options in September 2017 and 30,000,000 share options in March 2019 to eligible participants, all of which were accepted[127]. - The total number of share options outstanding as of December 31, 2025, is 2,247,000, with no options exercised during the period[143]. - The company’s share option scheme expired on November 17, 2023, and there are no other share schemes currently in force[145]. Social Responsibility and Community Engagement - The Group actively participated in public welfare activities and health education initiatives to enhance corporate reputation and fulfill social responsibilities[50][56].

呈交日期: 2026年3月2日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 大健康國際集團控股有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02211 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | 本月底法定/註冊股 ...

Core Viewpoint - The company reported a significant decline in revenue for the six months ending December 31, 2025, primarily due to adjustments in China's healthcare policies and intense market competition, although a reduction in sales and marketing expenses helped mitigate losses [1] Financial Performance - The company achieved revenue of 267 million yuan, representing a year-on-year decrease of 39.5% [1] - The net loss for the period was 6.1 million yuan, which is a reduction of 20.78% compared to the previous year [1] - The basic loss per share was 6.21 cents [1] Market Conditions - The decline in revenue was attributed to the impact of changes in China's healthcare insurance policies and heightened competition in the market [1] - The reduction in sales and marketing expenses provided some offset to the revenue decline [1]

Core Viewpoint - The company reported a significant decline in revenue and a reduced loss, attributed to changes in China's healthcare policies and intense market competition [1] Financial Performance - The company achieved revenue of 267 million yuan, a year-on-year decrease of 39.5% [1] - The loss for the period was 6.1 million yuan, which represents a year-on-year reduction of 20.78% [1] - Basic loss per share was 6.21 cents [1] Factors Influencing Performance - The decrease in revenue was primarily due to adjustments in China's healthcare policies and fierce market competition [1] - A reduction in sales and marketing expenses helped to offset some of the revenue decline [1]

Core Viewpoint - The company reported a significant decline in overall revenue and a reduction in losses compared to the previous year, primarily due to changes in China's healthcare policies and intense market competition [1] Financial Performance - The overall revenue for the six months ending December 31, 2025, was RMB 267 million, representing a year-on-year decrease of 39.5% [1] - The loss attributable to shareholders for the period was RMB 6.1 million, an improvement from a loss of RMB 8 million in the same period of 2024 [1] - The loss per share was RMB 0.0621, compared to RMB 0.1000 (restated) for the six months ending December 31, 2024 [1] Market Factors - The decrease in revenue was attributed to adjustments in China's healthcare insurance policies and fierce market competition [1] - A reduction in sales and marketing expenses helped to offset the revenue decline during the period [1]

Financial Performance - Revenue for the six months ended December 31, 2025, was RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million in the same period of 2024[3] - Gross profit for the same period was RMB 47.4 million, down 32.7% from RMB 70.4 million year-on-year[3] - Operating loss improved to RMB 3.4 million from RMB 7.9 million, reflecting a reduction of RMB 4.5 million[3] - Net loss for the period was RMB 6.1 million, an improvement of RMB 1.6 million compared to RMB 7.7 million in the previous year[3] - Basic loss per share was RMB 6.21, an improvement from RMB 10.00 in the same period last year[3] - The gross margin increased to 17.8%, up by 1.9 percentage points from 15.9%[3] - The retail business revenue for the group was RMB 90.9 million, a decrease of 23.5% compared to RMB 118.9 million in the same period last year[34] - The distribution business revenue declined by 45.4%, from RMB 322.3 million in the previous year to RMB 175.9 million[35] - The loss attributable to owners of the company was RMB 6.1 million, an improvement from a loss of RMB 8.0 million in the same period of 2024[43] Assets and Liabilities - Total assets as of December 31, 2025, amounted to RMB 484.4 million, compared to RMB 447.6 million as of June 30, 2025[7] - The total assets of the group as of December 31, 2025, amounted to RMB 484,364 thousand, with liabilities totaling RMB 142,316 thousand[18] - Trade receivables decreased to RMB 39,301,000 in 2025 from RMB 45,268,000 in 2024, a decline of approximately 13%[28] - Trade payables increased to RMB 66,645,000 in 2025 from RMB 53,048,000 in 2024, an increase of about 26%[29] Cash Flow and Financial Position - Cash and cash equivalents increased significantly to RMB 63.1 million from RMB 13.4 million[7] - The net cash flow from operating activities was RMB 21.1 million, an increase from RMB 8.7 million in the same period of 2024[56] - Total income tax expense decreased to RMB 908,000 in 2025 from RMB 1,793,000 in 2024, a reduction of approximately 49%[23] Operational Highlights - The group operates primarily in the Northeast region of China, with no single customer contributing more than 10% of total revenue[17] - The group has established three large-scale distribution logistics centers, enhancing logistics capabilities and regional service efficiency[38] - The group has a total of 660 distributors, focusing on optimizing customer structure and maintaining quality customer relationships[35] - The group recorded total revenue of RMB 266.8 million, a decrease of 39.5% compared to RMB 441.2 million in the same period of 2024[44] - The total number of retail pharmacies decreased to 115 from 182 in 2024, with a significant reduction in stores located in Heilongjiang Province from 155 to 91[46] - The active customer base in the national distribution network decreased to approximately 660 from 952 in 2024, with a notable drop in retail and clinic customers from 694 to 444[48] Cost Management - Cost of goods sold decreased to RMB 218,647,000 in 2025 from RMB 369,614,000 in 2024, representing a reduction of approximately 41%[21] - Employee benefits expenses decreased to RMB 23,002,000 in 2025 from RMB 38,802,000 in 2024, a decline of about 41%[21] - Selling and marketing expenses were RMB 32.8 million, a reduction of 45.3% from RMB 60.0 million in the same period of 2024, accounting for 12.3% of total revenue[51] - Administrative expenses decreased to RMB 18.1 million from RMB 18.6 million in the same period of 2024, representing a decline of 2.7%[53] Strategic Initiatives - The company plans to expand its business beyond mainland China to maximize shareholder returns and will prioritize evaluating feasible options[63] - The group aims to enhance its professional service capabilities and operational quality through a "Professional+" strategy, focusing on training a new generation of employees and integrating resources from renowned doctors[63] - The "Platform+" strategy will introduce value-added services in retail stores to meet the growing health management needs of consumers, leveraging technology and partnerships in the health sector[64] - The "Internet+" strategy will strengthen the integration of online and offline operations, utilizing mobile internet advantages to develop various marketing methods and enhance customer engagement[65] - The group is actively exploring the "Direct to Patient (DTP) pharmacy" strategy to adapt to the aging population and industry upgrades[33] Governance and Compliance - The board decided not to declare an interim dividend for the period, consistent with the previous year[66] - The company has complied with the corporate governance code but noted deviations regarding the separation of roles between the chairman and CEO, which are currently held by the same individual[67] - A subscription agreement was signed on May 13, 2025, for the issuance of 304,402,632 subscription shares, representing approximately 27.54% of the enlarged issued share capital, at a price of HKD 0.08 per share[69] - The audit committee, composed of three independent non-executive directors, reviewed the unaudited interim results for the period[70] - The interim results announcement will be published on the stock exchange and the company's website, containing all information required by the listing rules[71] - The board of directors consists of three executive directors and three independent non-executive directors[72]

Core Viewpoint - The company, Great Health International (02211.HK), has announced a board meeting scheduled for February 27, 2026, to approve its interim results for the six months ending December 31, 2025, and to consider the distribution of an interim dividend, if any [1] Group 1 - The board meeting will take place on February 27, 2026 [1] - The meeting will focus on approving the interim performance of the company and its subsidiaries for the six months ending December 31, 2025 [1] - The company will also consider the potential distribution of an interim dividend during this meeting [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 董事會會議通告 香港，二零二六年二月十三日 大健康國際集團控股有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零 二六年二月二十七日（星期五）舉行董事會會議，藉以（其中包括）審批本公司及其附屬公 司於截至二零二五年十二月三十一日止六個月的中期業績及其發佈，以及考慮派發中期 股息（如有）。 承董事會命 於本公告日期，董事會包括三名執行董事，分別為初川富先生、金東昆先生及趙澤華先 生；以及三名獨立非執行董事，分別為鄭雙慶先生、江素惠女士及鄒海燕先生。 大健康國際集團控股有限公司 主席兼執行董事 初川富 2211 ...

Group 1 - A total of 125 stocks reached a 52-week high as of February 9, with notable performers including Zhongmiao Holdings (107.50% increase), Southern Communications (48.48% increase), and Putian Communication Group (41.30% increase) [1] - The highest closing price recorded was for Zhongmiao Holdings at 39.520, with a peak of 41.500 [1] - Other significant stocks that reached new highs include KFM Jinde (19.23% increase), Baoji Pharmaceutical (18.20% increase), and Shenyang Public Development (18.18% increase) [1] Group 2 - The report also lists stocks that reached new lows, with Dajiankang International showing the largest decline at -18.67%, followed by China Technology Industry Group at -14.75% [4] - Other notable declines include FI II Southern Nikkei (-8.08%) and Zhuozheng Medical (-7.67%) [4] - The lowest closing price recorded was for Dajiankang International at 0.660, with a low of 0.610 [4]

Core Insights - The recent stock transfers of Da Health International (02211) indicate significant shareholder activity, with multiple large transactions occurring in January and early February 2023 [1] Group 1: Stock Transfers - On February 4, shareholders transferred shares worth HKD 5.274 million from Zhaoyin International Securities to Bank of China (Hong Kong), representing 5.30% of the total [1] - On January 20, 30.44 million shares were deposited into Yue Shang International Securities, with a market value of HKD 39.268 million [1] - On January 26, shares worth HKD 50.983 million were transferred to Zhaoyin International Securities, accounting for 12.43% of the total [1] - On January 28, shares valued at HKD 30.354 million were moved from Futu Securities International Hong Kong to Baoxin Securities [1] - On January 29, a transfer of shares worth HKD 85.515 million occurred from Yue Shang International Securities to HSBC Hong Kong, representing 14.68% of the total [1]